Yasuka Matsunaga

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Shirong Qiang, Yusuke Nakatsu, Yasuyuki Seno et al. · Diabetology & Metabolic Syndrome · 2015 · 113 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

<i>Lactobacillus casei</i>strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model

Hirofumi Okubo, Hideyuki Sakoda, Akifumi Kushiyama et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2013 · 103 citations

Life Sciences, Microbiology, Nutritional Sciences +15

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice

Yusuke Nakatsu, Hiroki Kokubo, Bumdelger Batmunkh et al. · International Journal of Molecular Sciences · 2017 · 89 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model

Yusuke Nakatsu, Yasuyuki Seno, Akifumi Kushiyama et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2015 · 86 citations

Life Sciences, Biochemistry, Pharmacology +16

Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice

Masa-ki Inoue, Yasuka Matsunaga, Yusuke Nakatsu et al. · Diabetology & Metabolic Syndrome · 2019 · 60 citations · Full text

Medicine, Biochemistry, Pharmacology +17